Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season.

Details

Request a copyRequest a copy
Serval ID
serval:BIB_0DB48862B6C0
Type
Article: article from journal or magazin.
Collection
Publications
Institution
UNIL/CHUV
Title
Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season.
Journal
The Journal of allergy and clinical immunology
Author(s)
Kettner A., DellaCorte G., de Blay F., Jacobsen L., Jutel M., Worm M., Charlon V., Simonsen K., Reymond C., Spertini F.
ISSN
1097-6825 (Electronic)
ISSN-L
0091-6749
Publication state
Published
Issued date
08/2018
Peer-reviewed
Oui
Volume
142
Number
2
Pages
678-680.e7
Language
english
Notes
Publication types: Clinical Trial, Phase II ; Letter ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
A short course of 5 injection AIT with Bet v 1 Contiguous Overlapping Peptides was well tolerated and improved allergic rhinitis during the 2 <sup>nd</sup> pollen season after treatment. Long lasting efficacy was associated with a persistent allergen-specific IgG4 response.

Keywords
Administration, Sublingual, Adult, Antigens, Plant/immunology, Antigens, Plant/therapeutic use, Betula/immunology, Desensitization, Immunologic/methods, Europe, Female, Follow-Up Studies, Humans, Hypersensitivity/immunology, Hypersensitivity/therapy, Male, Middle Aged, Peptides/immunology, Peptides/therapeutic use, Pollen/immunology, Quality of Life
OAI-PMH
oai:serval.unil.ch:BIB_0DB48862B6C0
DOI
10.1016/j.jaci.2018.01.052
Pubmed
29678749
Web of science
000440664400036
Create date
26/04/2018 17:46
Last modification date
12/09/2019 5:10
Usage data